Compare AbCellera Biologics Inc (ABCL) vs HSBC Holdings plc (HSBC) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

HSBC trades at $98.74, up 2.03% with bullish technical indicators and strong earnings momentum. The stock shows consistent earnings beats with Q1 2026 EPS of $2.20 exceeding expectations. Recent developments include strategic reviews of non-core businesses and AI partnerships with Google Cloud. Valuation metrics include a P/E of 16.32 and P/B of 1.72, while maintaining a 30.81% net income margin.

HSBC presents a balanced investment case with solid fundamentals and strategic repositioning offset by regulatory risks and market volatility. The bank's focus on core markets and AI integration supports growth potential, though recent regulatory penalties and business exits warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings.